Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 2, 2010 Brian Orelli	Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today.
The Motley Fool August 27, 2007 Brian Orelli	Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note.
The Motley Fool February 2, 2005 Rich Duprey	Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note.
The Motley Fool November 9, 2004 Charly Travers	Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works.
The Motley Fool July 26, 2004 Brian Gorman	Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble.
The Motley Fool December 1, 2008 Brian Orelli	Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now.
The Motley Fool May 3, 2005 Charly Travers	Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not.
The Motley Fool November 15, 2011 Brian Orelli	When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells.
The Motley Fool May 26, 2009 Brian Orelli	A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents.
The Motley Fool December 23, 2011 Brian Orelli	Geron's Hurry-Up-and-Wait Strategy Clinical trials started, now the waiting begins.
Bio-IT World Dec 2005/Jan 2006 Maureen McDonough	The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line.
The Motley Fool July 10, 2006 Brian Lawler	Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced.
The Motley Fool August 19, 2010 Brian Orelli	The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology.
The Motley Fool June 21, 2005 Brian Gorman	Stem Cell Chatter Despite the promise suggested by early studies, embryonic stem cell research remains highly speculative. More concrete results, not the amount of cash being poured into research, are the best basis for investing decisions.
The Motley Fool April 14, 2008 Brian Orelli	Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost.
Pharmaceutical Executive October 1, 2012 Ben Comer	Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures.
The Motley Fool December 22, 2009 Brian Orelli	Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year
The Motley Fool January 20, 2012 Dan Caplinger	Can Geron Recover in 2012? Let's look at this year's prospects for this company.
Scientific American January 17, 2007 Charles Q. Choi	A Stroke for Stem Cells The brain becomes a target in stem cell clinical trials.
The Motley Fool May 2, 2011 Brian Orelli	StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies.
The Motley Fool September 29, 2010 Brian Orelli	Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals.
The Motley Fool August 31, 2007 Brian Orelli	A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending.
The Motley Fool December 27, 2006 Brian Lawler	Telik Falls Short Shares of another biopharma fall after disappointing clinical trial results.
The Motley Fool May 15, 2007 Mike Havrilla	Secret Cytori Cytori may be a lesser-known player in the stem-cell therapy field, but it's a stock to watch in the coming year.
The Motley Fool October 19, 2009 Rich Smith	This Just In: Upgrades and Downgrades Merriman Curhan Ford thinks Geron could as much as double off today's price, primarily in response to successful data on GRN163L, a treatment that targets cancer agent telomerase.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool January 31, 2011 Brian Orelli	Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet.
The Motley Fool September 20, 2005 Rich Smith	ViaCell's Cancer Trial Snag The cord blood collector suffers a research setback. Investors should keep in mind that the real money-maker behind ViaCell is its ViaCord cord blood storage business.
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
Bio-IT World April 2006	Virtual Stem Cell Laboratory Goes Live Children's Hospital in Boston's Virtual Stem Cell Laboratory web site allows online visitors to manipulate and investigate a "living" culture of embryonic stem cells.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool January 4, 2005 W.D. Crotty	A StemCell First News of an FDA application sends StemCells' stock soaring.
Information Today July 9, 2015	The BMJ Requires Patient-Level Data for Publication The BMJ is now applying its data-sharing policy to all clinical trials.
The Motley Fool November 3, 2009 Rich Smith	This Just In: Upgrades and Downgrades Needham suspends clinical trial of buying Geron.
BusinessWeek January 23, 2006 Arlene Weintraub	A "Body Blow" To Stem Cell Research Funding for stem cell research in the U.S. wasn't so hot even before the Korean scandal broke.
The Motley Fool November 14, 2008 Brian Orelli	Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells.
Chemistry World August 7, 2013 Emma Stoye	AllTrials releases plan for clinical trial reporting The organizations behind AllTrials, a public campaign calling for detailed information on clinical trials to be publically available, have put together a detailed plan on how to achieve clinical trial reporting on a global scale.
Chemistry World September 2, 2014 Phillip Broadwith	Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer.
The Motley Fool December 8, 2011 Dan Caplinger	Has Geron Become the Perfect Stock? Geron has a modest pipeline of cancer drugs, including imetelstat, which is currently in phase 2 clinical trials.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
Bio-IT World August 2005 Ellen H. Julian	Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources.
Bio-IT World May 9, 2003 Mark D. Uehling	Data Rapture? Electronic capture of data: Some say it unclogs the medieval clinical trials process. Others remain skeptical of software and put their trust in paper.
Bio-IT World April 16, 2004 Mark Uehling	PDAs and Clinical Trials PalmOne's director of healthcare sales explains why clinical trials are driving sales of handheld devices.
Information Today July 2, 2013	Thomson Reuters Offers Clinical Trial Intelligence Solutions These solutions improve clinical trials, speed up product development and release, and help professionals strengthen portfolios and R&D strategy.
Reason October 2001 Ronald Bailey	Blastocyst Brouhaha Which human cells count as people?
The Motley Fool November 28, 2007 Brian Orelli	Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
Bio-IT World Dec 2006/Jan 2007 Mark D. Uehling	Vertex Views Trial Supplies For a recent clinical trail, the head of clinical development systems at Vertex Pharmaceuticals found a new software offering from Tourtellotte Solutions.
Pharmaceutical Executive March 1, 2013 Ken Getz	Building Clinical Trial Awareness for Patients: Why Not Try the Pharmacist? The author explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol.